1. Pink Sheet
  2. >>Product Reviews

Makena Randomized, Controlled Trial Proposal Shows Evolution In Covis’ Thinking

 
• By Sue Sutter

Just three years ago, then-sponsor AMAG Pharmaceuticals said another trial of the preterm birth prevention drug in the US would be unethical and infeasible. Now, AMAG parent Covis is proposing to conduct a new study designed to address the shortcomings of the PROLONG trial.

Apple
Covis is seeking another bite at the confirmatory trial apple to try to prove Makena's clinical benefit. • Source: Shutterstock

Covis Pharma is hoping to convince a US Food and Drug Administration advisory committee – and senior agency officials – that its preterm birth prevention drug Makena (hydroxyprogesterone caproate injection, also known as 17-OHPC or 17P) should stay on the market while it conducts a new US randomized, controlled trial designed to address the shortcomings of the PROLONG study.

The current study proposal is yet another milestone in the evolution of the product sponsor’s thinking about the need for, and feasibility of, conducting a new

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Post-Marketing Regulation & Studies

More from Product Reviews

FDA Adcomms Are Back: Four Cancer Drugs, COVID-19 Vaccine Formulations To Get Reviews

 
• By Sue Sutter and Bridget Silverman

The Oncologic Drugs Advisory Committee will meet for two days in mid-May, followed by a Vaccines and Related Biological Products Advisory Committee’s review of the 2025-2026 COVID-19 vaccine formulation.

Unlocking Opportunities: How To Engage With The EMA On Animal Testing Alternatives

 
• By Neena Brizmohun

The European Medicines Agency, like its counterpart in the US, is increasingly focusing on the use of alternatives to animal testing.

Opioid Safety: US FDA Hears Mixed Messages On Adding Posmarketing Studies To Labeling

 
• By Sue Sutter

Some advisory committee members said adding quantitative data on misuse, abuse, opioid use disorder and overdose to labeling would be helpful, but others worried the two epidemiological studies were not sufficiently generalizable to a broader population.